A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction
Crossref DOI link: https://doi.org/10.1007/s40256-016-0174-3
Published Online: 2016-06-04
Published Print: 2016-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Whalen, John D.
Davies, Glenn
Du, Mark
Oguz, Mustafa
Bash, Lori D.
Ozer-Stillman, Ipek
Funding for this research was provided by:
Merck
License valid from 2016-06-04